Bone Biologics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bone Biologics generated cash of -$9,555,904, which is less than the previous year. Cash used in financing activities reached the amount of $5,044,161 last year. Net change in cash is therefore -$4,511,743.
Cash Flow
| 2014 | -2.75M | 25.47K | 5.39M |
|---|---|---|---|
| 2015 | -3.54M | -504 | 2M |
| 2016 | -7.32M | 0 | 6.83M |
| 2017 | -3.33M | 0 | 3.4M |
| 2018 | -4.10M | 0 | 4.36M |
| 2019 | -3.25M | 0 | 2.32M |
| 2020 | -426.93K | 0 | 402.78K |
| 2021 | -1.22M | 0 | 7.90M |
| 2022 | -3.56M | 0 | 4.42M |
| 2023 | -9.55M | 0 | 5.04M |
BBLGW Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 7.53M | 6.67M | 0 | 24.14K | 955.37K | 690.27K | 620.37K | 1.11M | 2.66M | 1.53K |
Operating activities | ||||||||||
Net income | -8.94M | -1.48M | -1.61M | -1.82M | -3.42M | -4.43M | -7.05M | -21.02M | -13.87M | -4.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 50 | 96 | 96 | 700 | 4.45K | 280 |
Stock-based compensation expense | 152.59K | 266.63K | 207.03K | 0 | 49.69K | 0 | -584.02K | 3.46M | 3.70M | 256.64K |
| Deferred income tax benefit | 152.59K | 266.63K | 207.03K | 0 | 49.69K | 0 | -584.02K | 3.46M | 3.70M | 256.64K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75 | -75 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 255.87K | 788.55K | -365.48K | 333K | -64.82K | -66.90K | 0 | 73.33K | 194.46K | 0 |
Cash generated by operating activities | -9.55M | -3.56M | -1.22M | -426.93K | -3.25M | -4.10M | -3.33M | -7.32M | -3.54M | -2.75M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -504 | -11.90K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -504 | 25.47K |
Financing activities | ||||||||||
Common Stock Issued | 5.04M | 4.42M | 6.85M | 0 | 0 | 0 | 700K | 0 | 0 | 480K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -10.60K | -402.78K | 2.32M | 0 | 2.7M | 3.08M | 2M | -893.37K |
Cash used in financing activities | 5.04M | 4.42M | 7.90M | 402.78K | 2.32M | 4.36M | 3.4M | 6.83M | 2M | 5.39M |
Net Change In Cash | -4.51M | 862.94K | 6.67M | -24.14K | -931.22K | 265.09K | 69.90K | -494.73K | -1.54M | 2.65M |
Cash at end of period | 3.02M | 7.53M | 6.67M | 0 | 24.14K | 955.37K | 690.27K | 620.37K | 1.11M | 2.66M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |